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Objective and design: Primary aldosteronism (PA) represents the most common cause
of secondary hypertension. A higher risk of cardiovascular events has been reported in
patients with PA than in otherwise similar patients with essential hypertension (EH). So far,
only a few studies investigated the electrocardiographic changes in PA patients compared
to EH patients.
Methods: To investigate the electrocardiographic changes and heart remodeling in PA,
we enrolled 61 consecutive patients, 30 with PA [12 with aldosterone-producing adrenal
cortical adenoma (APA) and 18 with bilateral adrenal hyperplasia-idiopathic adrenal hyper-
plasia] and 30 with EH. In all subjects, electrocardiographic parameters were evaluated
from 12-lead electrocardiograms and heart remodeling with echocardiogram.
Results: No significant differences in age, sex, body mass index, and blood pressure were
found in two groups. The P wave and PR interval duration were significantly prolonged in
patients with PA respect to EH (p<0.003 and <0.002, respectively). A first degree atrio-
ventricular block was present in 16% of the patients with PA and only in 3.2% of those with
EH. In PA patients, the interventricular septum thickness (IVST) correlated with PR duration
(r =0.51; p<0.03). Left ventricular hypertrophy was present in 53% of the patients with
PA and in 26% of the patients with EH ( 2χ , p<0.03).
Conclusion: In this case–control study, patients with PA show more anatomic and electri-
cal heart remodeling than those with EH. We hypothesize that in patients with PA these
cardiac changes may play a role for the increased risk of future cardiovascular events.
Keywords: hyperaldosteronism, essential hypertension, electrocardiography, left ventricular hypertrophy,
conduction disturbance
INTRODUCTION
Primary aldosteronism (PA) is a common cause of secondary
arterial hypertension accounting for 5–15% of all hypertensive
patients in special centers (1–5). It is of particular importance
to diagnose or rule out this condition, as hypertensive patients
affected by PA can be cured with adrenalectomy or appropriate
medical therapy (mineral-corticoid receptor (MR) antagonists) in
case of APA and/or idiopathic adrenal hyperplasia (IHA) (6). This
is relevant, as it has been demonstrated that patients with aldos-
terone excess are more prone to stroke, myocardial infarction, and
atrial fibrillation than are essential hypertensives (EH) with risk
profiles (7, 8).
Several studies have shown that patients with PA have a higher
risk for target organ damage than other EH patients [such as left
ventricular hypertrophy (LVH), QT interval prolongation, and
prevalence of metabolic syndrome (SM)] (9–11). This effect is
partially independent of blood pressure change (12), but probably
determined by the effect of aldosterone excess (13).
These non-epithelial effects of aldosterone supports the con-
cept that blood pressure and hemodynamic overload are not only
factors involved in the genesis of organ damage such as LVH.
In fact, aldosterone contributes to cardiovascular remodeling via
non-genomic processes, locally synthesized in blood vessel con-
tributes to the hypertrophy of vascular smooth cells (VMMC)
(14), and determined alteration to the geometry of myocardial
cells with cell proliferation and fibrosis (15).
Moreover, many studies have been performed to evaluate the
heart remodeling in PA patients, but until now only few stud-
ies have investigated the electrocardiographic changes in those
patients independent at the levels of serum potassium.
Based on the electrophysiological aldosterone modifications in
cardiac myocytes and fibers of conduction system (16), the aim
of this study was to investigate electrocardiographic changes and
heart remodeling in PA patients compared to EH patients.
MATERIALS AND METHODS
PATIENTS
Sixty-one adult patients (39 males and 22 females) were enrolled:
30 patients with PA (12 with APA and 18 with IHA) and 31 patients
with EH. All patients have been referred to the Specialized Center
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of Secondary Hypertension, Department of Internal Medicine and
Medical Specialities, University of Rome “Sapienza”, Italy.
This study was approved by our ethical committee, and
informed consent was obtained from all subjects before their
enrollment.
DIAGNOSIS OF PRIMARY ALDOSTERONISM
After 2 weeks of following a normal sodium (140–150 mEq/day)
and potassium intake (40–50 mEq/day), fasting blood samples for
plasma aldosterone concentration (PAC) and plasma renin activity
(PRA) were obtained in all subjects.
Patients were supine for at least half an hour. All anti-
hypertensive drugs were withdrawn at least 3 weeks (up to
2 months for anti-aldosterone drugs) before hematochimic, bio-
chemical, and hormonal evaluation.
In hypertensive patients whose treatment could not be with-
drawn for ethical reasons, calcium-channel blockers (nifedipine or
amlodipine) or α-1-receptor blockers (doxazosina) were utilized
at doses required to achieve blood pressure control. These agents
are considered to have a neutral effect of rennin–angiotensin
aldosterone system (RAAS).
Diagnosis of PA was made as described previously (10). A
cut-off PAC/PRA ratio of more than 40 (ng/dl: ng/ml/h) in
the presence of PAC higher than 15 ng/dl and suppressed PRA
(≤0.2 ng/ml/h) was used as a screening for PA. In the case of a
PAC/PRA ratio greater than 40 (ng/dl:ng/ml/h), patients under-
went a saline infusion (0.9% NaCl 500 ml/h for 4 h) as a confirma-
tory test, and only those with PAC levels that failed to decrease to
<5 ng/dl after the saline infusion were diagnosed as having PA. An
imaging test comprising high-resolution computed tomography
(CT) with 3 mm slices and systematic use of a contrast medium
and/or magnetic resonance imaging (MRI) was mandatory in all
patients with a positive test and PA ≥5 ng/dl after saline infusion.
In all cases, the diagnosis of APA was confirmed by histopatho-
logical diagnosis, while IHA diagnosis was performed by technical
imaging (e.g., adrenal vein sampling).
ESSENTIAL ARTERIAL HYPERTENSION
The diagnosis of EH was established based on the absence of
clinical history and laboratory data of secondary hypertension:
principally normal values or plasma and urinary electrolytes, renal
function, urinary metanephrines, the RAAS, urinary free corti-
sol, and calcium-phosphorus system. All patients with white coat
hypertension were excluded from the study.
ELECTROCARDIOGRAM
All patients underwent a 12-lead resting electrocardiogram (ECG)
with PC ECG NORAV 1200 MEDICAL Ltd. using a specific soft-
ware, the following parameters have been calculated: amplitude
and duration of P wave, PR interval duration, and amplitude and
duration of QRS complex, QT interval, QT interval corrected for
the previous cardiac cycle length (QTc) by Bazett formula and QT
dispersion (QTd).
ECHOCARDIOGRAM
All patients underwent transthoracic echocardiograms performed
by the same operator with 3.5 MHz probe, II armonica, Toshiba
Sonovue 8000. Two different readers measured all of the echocar-
diograms, in a blind manner, the average of two calculations
was considered for the study of the left ventricular (LV) inter-
nal dimensions, interventricular septum (IVS), and posterior wall
thickness were measured according to the recommendations of the
American Society of Echocardiography (17) and derived anatomic
variables were calculated (15). Left ventricular mass index (LVMi)
was obtained by normalization of LVM for height to the 2.7 power,
and LVH was prospectively defined as a value of LVMi≥50 g/m2.7
in males and 47 g/m2.7 in females (18). Ejection fraction, endo-
cardial, and midwall fractional shortening (FS) were calculated
by standard methods (19). LV end-diastolic and end-systolic val-
ues were calculated with the Teicholz’s correction of the cube
formula (20).
DIAGNOSIS OF METABOLIC SYNDROME
Metabolic syndrome was defined according to Adult Treatment
Panel III (21) criteria, and its diagnosis required three or more of
the following conditions: (1) waist circumference >102 cm in men
and >88 cm in women, (2) triglycerides of 150 mg/dl or higher, (3)
high-density lipoprotein (HDL)-cholesterol <40 mg/dl for men
and <50 mg/dl for women, (4) fasting glucose of 100 mg/dl or
more, and (5) systolic BP of 130 mmHg or more and diastolic BP
of 85 mmHg or more.
BIOCHEMICAL MEASUREMENTS
Plasma renin activity was measured by radioimmunoassay (RIA)
using commercial kits (RenCTK: Sorin Biometrics). Normal range
sitting at rest, on normal sodium diet was 0.2–2.8 ng/ml/h; intra-
assay and inter-assay coefficients of variations (CVs) were within 8
and 10%, respectively. The assay for PAC was performed with diag-
nostic kits (Aldosterone Mirya, Technogenetics). Normal range
was 1–15 ng/dl supine, 3–32 ng/dl upright on a normal sodium
diet; intra-assay and inter-assay CV, where both<5–6%; the cross-
reactivity of the antibody for aldosterone for other adrenal steroids
was <0.001%.
EXCLUSION CRITERIA
Patients with non-sinus rhythm, advanced atrio-ventricular
block, bundle branch block, coronary artery disease (CAD),
structural abnormalities of heart and those on antiarrhyth-
mic, ACE-inhibitor or angiotensin receptor blocker therapy,
renal failure (GFR-MDRD <60 ml/min), liver failure, diabetes,
peripheral artery disease (ABI< 0.9), hypo-hypercalcemia, hypo-
hypermagnesiemia were excluded.
STATISTICAL ANALYSIS
Saphiro Wilk test was used to check the assumption of normal-
ity of the variables. Student’s test was used for the two groups’
comparison of continuous variables, while χ2 test was used for
categorical variables. Person’s rho was calculated to analyze asso-
ciation between electrocardiographic parameters; the dependent
variables have been the following factors: sex, age, body mass
index (BMI), SM, smoke, serum potassium levels, as independent
variables. All statistical comparisons were performed using two-
tailed significant tests, with p≤ 0.05, was considered statistically
significant. STATA was used for all analysis.
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RESULTS
Demographic and hemodynamic data are reported in Table 1. No
significant differences for age, gender, BMI, systolic and diastolic
blood pressure, and heart rate were found between PA and EH
patients. Moreover, we did not reveal a significant prevalence in
both groups for SM (Table 1).
As shown in Table 1, serum potassium levels were significantly
different between PA patients (3.99± 0.68 mEq/l) and EH patients
(4.27± 0.37 mEq/l) (p< 0.05, respectively). Moreover, in patients
with PA, we found a significant increase of serum creatinine val-
ues (1± 0.19 mg/dl) compared to EH patients (0.86± 0.15 mg/dl)
(p< 0.001, respectively). As expected, PAC and PRA levels were
significantly altered in PA patients compared to EH patients, and
in particular PAC/PRA ratio was significantly increased (84.3± 79
vs. 17.6± 15 ng/dl:ng/ml/h; p< 0.0002, respectively).
The P wave and PR interval duration were significantly pro-
longed in patients with PA compared to EH patients (p< 0.003
and <0.02, respectively) (Table 2). In Table 3, we reported the
statistical differences of the echocardiographic parameters in the
two study groups.
Table 1 | Statistical differences in demographic characteristics and
laboratory data in two groups of patients (values are expressed as
mean±SD).
Parameter PA (n=30) EH (n=31) p
Age (years) 55±11 54±10 NS
Gender (male/female) 8/22 16/14 NS
Body mass index (kg/m2) 26.9±4 25.1±3 NS
SBP/DBP 135±17/82±10 129±11/79±6 NS/NS
Heart rate (bpm) 70±10 70±8 NS
Glycemia (mg/dL) 92±13 94±18 NS
Metabolic syndrome 11/30 8/31 NS
Serum K+ (mEq/dL) 3.99±0.68 4.27±0.37 <0.05
Creatinine (mg/dL) 1±0.19 0.86±0.15 <0.001
PAC (ng/dl) 426±422 104±60 <0.0001
PAC/PRA (ng/dl:ng/ml/h) 84.3±79 17.6±15 <0.00002
PA, primary aldosteronism; EH, essential hypertension; SBP/DBP, systolic and
diastolic blood pressure; PAC, plasma aldosterone concentration; PAC/PRA,
plasma aldosterone/plasma renin activity; NS, not significant; p<0.05 is con-
sidered statistically significant.
Table 2 | Statistical differences in electrocardiographic parameters in
two groups of patients (values are expressed as mean±SD).
Parameters PA (n=30) EH (n=31) p
P wave (ms) 108.7±13.7 92.4±12.8 <0.01
PR interval (ms) 177.9±30.6 152.3±19.5 <0.02
QRS interval (ms) 85.5±21.4 75.2±11.5 <0.04
QTc interval 406.7±29.8 404.9±16.0 NS
QTd 41.4±29.0 38.9±22.5 NS
PA, primary aldosteronism; EH, essential hypertension; p<0.05 is considered
statistically significant.
First degree atrio-ventricular block was present in 16% of PA
patients, but only in 2–3% patients with EH (p= 0.09). In PA
patients, PR duration positively correlated with IVS (r = 0.51,
p< 0.03), and IVS with LVMi (r = 0.54, p< 0.04) (Figure 1).
Primary aldosteronism patients showed a significant increase
of the QRS duration compared to EH patients (p< 0.04). This
increase was not significantly revealed in PA patients when
multivariate analysis was performed.
QTc interval, calculated according to Bazett’s Formula, did not
differ significantly between the two groups. However, patients with
corrected QTc >440 ms were affected by PA. Finally, the degree
of QTd in PA patients remained unchanged compared with EH
patients (Table 2).
DISCUSSION
In the present study, we demonstrated a positive correlation
between PR interval and both IVT and LVMI cardio-parameters
in patients with PA, and we hypotheses that the electrical abnor-
malities can be related to myocardial remodeling in this disease
secondary, in part, to aldosterone hypersecretion.
In the last years, many studies have been performed in PA in
order to investigate the effects of aldosterone on cardiovascular
Table 3 | Statistical differences of the echocardiographic parameters in
two groups of patients (values are expressed as mean±SD).
Parameters PA (n=30) EH (n=31) p
LVM (g) 218.7±53.5 185.9±42.3 <0.01
LVMi (g/m2.7) 50.7±11.4 45.2±10.1 <0.05
IVS (mm) 11.3±1.3 10.0±1.2 <0.01
PW (mm) 10.7±1.4 9.6±1.2 <0.01
PA, primary aldosteronism; EH, essential hypertension; LVM, left ventricular
mass; LVMi, left ventricular mass index; IVS, interventricular septum thickness;
PW, posterior wall thickness; p< 0.05 is considered statistically significant.
FIGURE 1 |The graph represents the linear regression between
interventricular septum (IVS) wall thickness and PR interval duration
in patient with primary aldosteronism.
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system, in terms of CAD, LV function, arterial stiffness, and
arrhythmias (7, 8, 12).
For a long time, PA has been considered a relatively benign form
of arterial hypertension, but recent studies suggest that chronic
exposure to aldosterone might lead to cardiovascular and renal
damage (11). In fact, PA patients display unfavorable cardiovas-
cular profiles, suggesting that aldosterone may play an additional
role beyond its well-known hypertensive effects. Extensive exper-
iments using animal models have demonstrated that aldosterone
co-stimulate an abnormal accumulation of collagen (type I and
Type II), which can be reversed partially by a treatment with
spironolactone, an MR antagonists. In particular, a study by Brilla
et al. (17) demonstrated that an aldosterone infusion with a
high salt-intake induces both cardiac hypertrophy and myocardial
interstitial fibrosis. In clinical studies, Rossi et al. (15) reported that
PA patients exhibit significant changes in the myocardial tissue as
compared to EH patients, and secondary to cardiac fibrosis, can
serve as an important determinant of myocardial remodelling and
impaired tissue stiffness. Thus, patients with PA exprimed more
cardiovascular alterations that EH patients, not only due to blood
pressure, suggesting that aldosteronism status represents “per se”
an independent factor for cardiovascular modifications with depo-
sition of collagen fibers in myocardial texture and electrical cardiac
conduction (7). Three mechanisms have been proposed to explain
the slow cardiac conduction secondary, in part, to myocardial
fibrosis: (1) reducing sodium current; (2) reducing cell-to-cell
coupling with down-regulation of the number of connexins (such
as CX43), and (3) barriers of micro-fibrosis that reduces transfer
coupling (16).
Our previous study showed that PR interval was particularly
large in PA patients compared to EH patients. In particular, PR
interval prolongation was positively correlated with IVS thickness,
but PR interval could be also related to hypokalemia or specific
pharmacological therapy. Potassium plays an important role in
maintaining the electrical potential across the cellular membrane,
as well as in the depolarization and repolarization of the myocytes.
In particular, hypokalemia can have dramatic effects on the car-
diac cell conduction and may lead to observable changes on the
ECG. Moreover, as the serum potassium levels delaine, the trans-
membrane is an elevation in the resting membrane potential and
a prolongation of the action potential (particularly in phase 3
repolarization) and the refractory periods (18). As a result of
the increased duration of the activation potential and the refrac-
tory period, patients with hypokalemia have an increased risk for
arrhythmias.
Regarding the drugs treatment for arterial hypertension, in our
study all patients (PA and EH) were treated with dihydropiridine
calcium-antagonists and/orα-1 blockers which do not have partic-
ular effects on cardiac conduction system. Moreover, in our study,
an increase of QTc length (even into range normality) was found
in PA patients compared to EH patients. Additionally, we found a
positive correlation between QTc prolongation and PAC levels in
PA patients. The data were, in part, similar with the one reported
by Maula et al. (9), which revealed that almost half of the patients
with PA exhibited a pathological QTc length (>440 ms).
We speculated that aldosterone effect through non-genomic
pathway, associated with an increase of second biochemical
messengers, such as calcium or inositol triphosphate, may deter-
mine a prolongation of cardiac potential. Cardiac ion channels
have lipophilic domain capable to bind steroid hormone with
consequently activation or blocking ion channels themselves. Ion
causes alteration, though a prolongation of 2 and/or 3 phase of
potential action can increase the generation of post-repolarization
potentials and a QT prolongation, with potentially ventricular
arrhythmias (19). A difference in QTd was non-found in our
study groups, which means that a homogenous repolarization was
preserved that these data were in argument with another study
performed by Youg et al. (20) that revealed no significant differ-
ence for QTd prolongation in PA and EH groups. Moreover, it
demonstrated that pharmacological treatment with spironolac-
tone decreases QTd in patients with heart failure, and reduces the
risk of sudden death in patients with infarction myocardial acute
(IMA) and heart failure (21–23).
Finally,we revealed a significant increase of LVHi in our patients
with PA compared to EH patients. These results confirm and
extend other studies reported in the literature (24–27). The LVH
to the increased after-load of patients with high blood pressure
by developing LVH, which predicts cardiovascular events (28) and
should be regressed to improve prognosis (29). Aldosterone is the
key to LVH development: apart from affecting pre-load and after-
load in the setting of a high sodium intake, it augments the effects
of angiotensin II on AT-1 receptors (30,31),and also causes inflam-
mation and fibrosis (30). Altogether, these actions can explain
both the worse prognosis of patients with PA compared to EH
patients (7) and the survival benefit conformed by MR antagonists
in patients with LV remodeling (21, 22).
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